Interventional Cardiology

Coronary Therapies

The medical device industry’s most complete portfolio of PCI products

Together we can strengthen quality outcomes, increase operational efficiencies, and improve financial health in your cardiovascular service line (CVSL).

30%

Of all U.S. PCI patients present with calcium

20%

Of all U.S. PCIs are complex

~60%

Higher reimbursement for complex PCI vs. standard PCI**

Medical professional helping a paitent in a wheelchair down a hallway.

If complex PCI is a focus, we can help. As a category leader in Interventional Cardiology, Boston Scientific brings the most comprehensive portfolio of PCI products, education programs, and healthcare solutions and partnerships. Work with us to:

A full portfolio of cutting-edge solutions for complex coronary cases

As a hospital administrator, you understand the importance of staying at the forefront of medical technology. Boston Scientific’s comprehensive portfolio of coronary therapies empowers your cardiovascular service line to deliver exceptional patient outcomes.

Tools to see, prep, and treat because no two patients are the same.

A category leader in coronary therapies

See the Vessel

See the vessel

Assess plaque type and severity with state-of-the-art tools that reveal the patient’s physiological state. Clearer images of coronary arteries make for clearer treatment decisions.

Image of monitor displaying AGIGGO+ software

AVVIGO+

Fast. Intuitive. Accurate.
Integrates Intravascular imaging (IVUS) and physiology procedures into one streamlined platform.

Image of Opticross HD

Opticross HD
High definition IVUS imaging for precise visualization of coronary lesions. Leverage the power of AI with our cutting edge software that drives efficiency and accuracy.

Explore imaging
Prep the Vessel

Prep the vessel

Proper lesion preparation is critical for optimizing outcomes in complex PCI. Access best-in-class tools to modify calcium and tackle a coronary occlusion.

Image of WOLVERINE coronary ctting ballon

WOLVERINE™
Coronary Cutting Balloon™

Optimizes vessels preparation in complex cases and ensures appropriate stent apposition.

Image SYNERGY MEGATRON™: Drug-eluting stent with mega strength

ROTAPRO™
Rotational Atherectomy System

Easy to use rotational atherectomy system for the treatment of calcified lesions.  

Explore vessel prep
Treat the Vessel

Treat the vessel

Market-leading therapies to handle any form of coronary artery disease.

Image of AGENT medical device

AGENT™
Drug-Coated Balloon

The first and only U.S. coronary drug-coated balloon, AGENT introduces a new option for patients with in-stent restenosis without additional layers of metal.

Explore drug-eluting therapies

Optimizing IVUS in Clinical Practice

Insights from leading cardiologists

Discover expert insights on complex PCI and the use of intravascular ultrasound (IVUS). Learn about clinical practice details and optimal IVUS application from top specialists.

Explore expert insights

Impact of intravascular imaging on PCI outcomes

A network meta-analysis presented by Dr. Gregg W. Stone, MD at the European Society of Cardiology Congress 2023 highlighted significant benefits of using intravascular imaging for percutaneous coronary intervention (PCI). The study, which included 20 randomized trials and a total of 12,428 patients with a mean follow-up of 26.4 months, demonstrated that PCI guided by intravascular imaging (IVUS or OCT) markedly outperforms angiography guidance alone.8

  • 31% reduction in the primary composite outcome of target lesion failure
  • 46% reduction in cardiac death
  • 20% reduction in target vessel myocardial infarction
  • 29% reduction in target lesion revascularization
  • 52% reduction in stent thrombosis

This meta-analysis supports that incorporating intravascular imaging into PCI procedures can significantly improve patient outcomes, making it a compelling option for cardiologists around the world.

41%

Relative risk reduction for TLF

An AGENT of change for patients with in-stent restenosis

Data from the first coronary drug-coated balloon (DCB) study in U.S. met the 1-year primary endpoint and demonstrated low adverse event rates. 

Statistically Superior Outcomes Compared to Balloon Angioplasty
With the primary endpoint achieved, AGENT DCB demonstrated statistically superior outcomes compared to balloon angioplasty for target lesion failure (TLF) at 1-year.

Significant Risk Reduction
The use of AGENT DCB resulted in an approximate 41% relative risk reduction in TLF, underscoring its potential as a game-changing treatment for in-stent restenosis (ISR).

Read the trial results (PDF)

Coronary Therapies reimbursement

Coding and Payment Guides

Find additional information on coding, payment guides, and reimbursement information for inpatient, outpatient, office, and ASC settings.

View coronary therapies reimbursement

Coronary Therapies resources

Coronary Therapies product catalog

View catalog

Contact us

Get in touch with a sales representative to discuss how our portfolio of product and solutions can deliver measurable outcomes in the cardiovascular service line.

Contact Form

References:

**CY2021 CMS national base rate is $16,064 for APC 5194 vs. $10,043 for APC 5193. Actual rates will vary geographically and/or by individual facility
1. Presented by Pedro Lemos, MD at TCT2019
2. Kogame N, et al. J Am Coll Cardiol Intv. 2020;13:2251-62. DOI: 10.1016/j.jcin.2020.06.023
3. Presented by Giulio Stefanini, MD at EuroPCR 2021. This study evaluated the safety of the SYNERGY BP Stent with 1-month DAPT in high bleeding risk (HBR) patients
4. Pivato C.A., et al. J Am Heart Assoc. 2022;11:e023454. DOI: 10.1161/JAHA.121.023454
5. The SYNERGY BP Stent HBR indication is supported by the EVOLVE Short DAPT data. The HBR indication excludes SYNERGY XD 48 mm